Skip to content

Advertisement

  • Research
  • Open Access

Genetic variant in CXCL12 gene raises susceptibility to HPV infection and squamous intraepithelial lesions development: a case-control study

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2 and
  • 1Email authorView ORCID ID profile
Journal of Biomedical Science201825:69

https://doi.org/10.1186/s12929-018-0472-y

  • Received: 11 April 2018
  • Accepted: 10 September 2018
  • Published:

Abstract

Background

Human papillomavirus (HPV) is the most common sexually transmitted virus in women worldwide. The persistence of the virus may cause warts that are considered benign lesions and low or high grade intraepithelial lesions (LSIL/HSIL). Immunological system plays an important role in the resolution of infections. In this context, we highlight the chemokines, which are important regulators in the development of viral infections and inflammation. Among which CXCL12 stands out, due to its pro-inflammatory features, acting as chemoattractant recruiting immune cells. Several polymorphisms were identified in CXCL12 gene including rs1801157 in the 3′-untranslated region, which is characterized by a substitution of a guanine for an adenine.

Methods

In this study, 195 women were classified as HPV non-infected and 169 as HPV-infected. HPV-DNA was detected by polymerase chain reaction (PCR) and the polymorphism was assessed in blood cells through restriction fragment length polymorphism analysis.

Results

HPV infection was more incident in women who had more than 4 sexual partners during lifetime (p = 0.007), among those who presented lower number of pregnancies (p = 0.017). HPV was more prevalent among allele A carriers confirmed by logistic regression analysis adjusted for several confounding factors [ORADJ = 4.985; CI95% (2.85–8.72), p < 0.001]. An association between allele A carriers and HSIL development (p = 0.003) was also observed.

Conclusions

In the present study, we demonstrated that CXCL12 rs1801157 is independently associated with HPV infection and exerts influence in HSIL development, suggesting it as a promising susceptibility biomarker for HPV infection and lesions development.

Keywords

  • CXCL12
  • rs1801157 polymorphism
  • HPV infection
  • Cervical lesion

Background

Human papillomavirus (HPV) is the most common sexually transmitted infection in women worldwide. Infection may resist asymptomatic and is, usually, transient. Most of the women eliminate the virus from the body with the immune system effective action within 5–15 months [1]. The virus persistence may cause warts that are considered benign lesions, low or high grade squamous intraepithelial lesions (LSIL/HSIL) and cancer [2]. Several HPV types, especially high-risk types (HPV-HR), mediate squamous intraepithelial lesion (SIL) development that may progress to cervical cancer through several mechanisms such as keratinocytes malignant transformation, however many other factors contribute to the disease progression, such as tobacco use, long-duration oral contraceptive use and multiparity [3].

Moreover, immunological system plays an important role in the infection resolution. HPV-HR presence may not be elucidated and persist through several years, inducing an inflammatory microenvironment leading to pre-cancerous lesions development [46]. It is known that chemokines are important regulators in the development of viral infections [7] and are also responsible for inducing directional keratinocyte migration, notably of leukocytes during inflammation. Prolonged inflammation may facilitate carcinogenesis by providing an ideal microenvironment for tumor growth and development [8]. Several chemokines play important role in inflammation process, including CXCL12 due to its pro-inflammatory characteristic, acting as chemoattractant to immune cells such as lymphocyte [9].

The CXCL12 gene is located on long arm of chromosome 10 and was first cloned from a bone marrow-derived stromal cell line and then, identified as pre-B cell growth stimulating factor [10]. Several polymorphisms were identified in CXCL12 gene including rs1801157 in the 3′-untranslated region (3’UTR), described for the first time by Cheryl Winkler in 1998, and is characterized by a substitution from guanine to adenine (g.17289G > A) [11]. This single nucleotide polymorphism (SNP) was associated to elevated risk of some types of cancer development including breast cancer and lymphoma [12]. However, to date, there is no study between CXCL12 rs1801157 polymorphism and HPV infection as well as cervical lesions development.

In a case-control study the rs1801157 polymorphism was not associated with invasive squamous carcinoma and adenocarcinoma in situ [13]. On the other hand, analysis between this polymorphism genotype distribution and cervical cancer risk, showed that allele A of this polymorphism may be a risk factor for patients with a positive history of tobacco smoking [14].

Due to the lack of data, we aimed to investigate the influence of CXCL12 rs1801157 polymorphism on HPV infection and LSIL and HSIL development in a Brazilian population.

Methods

Ethical approval and sample characterization

This study was approved by Institutional Ethics Committee Involving Humans at State University of Londrina, Londrina – Paraná (PR), Brazil (CEP/UEL 133/2012; CAAE 05505912.0.0000.5231). The study purpose and procedures were explained to all patients and written informed consent was obtained.

Between 2014 and 2016, 364 women were enrolled in this case control-study. They were recruited in health services in Londrina- PR, Brazil: the Intermunicipal Consortium of Health of the Middle Paranapanema, Clinic center of the State University of Londrina, and from two basic health-care units in Londrina – PR, Brazil. After sample collection, cytobrushes containing cervical cells were stored in 2 mL TE buffer (10 mM Tris-HCl, 1 mM EDTA pH 8.0) at − 20 °C until DNA extraction. Peripheral blood was collected with EDTA as anticoagulant and stored at 7 °C. Structured questionnaire was applied concerning sociodemographic, reproductive and sexual behavioral data. Participants were stratified based on HPV DNA presence or absence. Cervical cytology results were collected from medical records.

Genomic DNA extraction

Genomic DNA was obtained from cervical cytobrushes using DNAzol (Invitrogen™ Inc., Carlsbad, CA, USA) according to the manufacturer’s instructions, and from peripheral blood using Biopur Mini Spin Plus Kit (Biometrix®, Curitiba, PR, Brazil). DNA concentration was measured at 260 nm on a NanoDrop 2000c™ Spectrophotometer (Thermo Fisher Scientific, Walthan, MA, USA), and purity was assessed by absorbance ratio measured at 260 nm and 280 nm.

HPV detection

HPV was detected by Polymerase Chain Reaction (PCR) using the primers MY09 (5’-CGTCCMAARGGAWACTGATC-3′) and MY11 (5’-GCMCAGGGWCATAAYAATGG-3′), which are designed to amplify a conserved region of approximately 450 bp in the HPV L1 gene [15]. Reaction conditions were 190 nM of dNTPs, 500 nM of each primer, 2 mM of MgCl2, 1X of Buffer (200 mM Tris-HCL, 500 mM KCl), approximately 80 ng of DNA and 1.25 U of Taq polymerase (Invitrogen™), with an annealing temperature of 55 °C. β-globin gene amplification (268 bp) was performed as an internal control, using primers GH20 (5’-GAAGAGCCAAGGACAGGTAC-3′) and PC04 (5’-CAACTTCATCCACGTTCACC-3′) [16] under the same conditions of HPV PCR. Reactions without template DNA were used as negative control to test for contamination, and DNA from HeLa cells, which are stably integrated with HPV18, was used as positive control. PCR products were electrophoresed on 10% polyacrylamide gel and stained with silver nitrate (Fig. 1).
Fig. 1
Fig. 1

Electrophoretic profile of amplified HPV DNA fragment. 10% polyacrylamide gel stained with silver nitrate. M, 100 bp marker ladder; 1 and 2, negative control for HPV; 3 and 4, positive control; 5 and 6 negative patient for HPV detection; 7 and 8, positive patient for HPV detection; 9 and 10 negative control for β-globin. Each patient has two columns, the first for b-globin (268 bp) and the second for HPV amplification (~450pb)

CXCL12 rs1801157 polymorphism genotyping

Genomic DNA from peripheral blood samples was used to detect CXCL12 rs1801157 polymorphism by PCR. Primers used for CXCL12 gene amplification were designed according to the nucleotide sequence deposited in GenBank which code is L36033. The primers forward (5’ CAGTCAACCTGGGCAAAGCC 3′) and reverse (5’ CCTGAGAGTCCTTTTGCGGG 3′) were utilized to amplify part of the 3’UTR of CXCL12. PCR conditions were 100 nM of dNTPs, 250 uM of each primer, 1.5 mM of MgCl2, 1X of Buffer, approximately 100 ng of DNA and 1 U of Taq polymerase (Invitrogen™) (Fig. 2).
Fig. 2
Fig. 2

Electrophoretic profile of amplified CXCL12 fragment. 10% polyacrylamide gel stained with silver nitrate. M, 100 bp marker ladder; 1, negative control; Columns 2 to 5, samples showing CXCL12 DNA amplification

The CXCL12 product amplification corresponds to a 293 bp fragment. The enzymatic restriction was performed by PCR-RFLP using PCR product in the presence of the restriction enzyme MspI (New England Biolabs, Ipswich, MA, USA). This enzyme cleaves the amplified fragment of DNA in the presence of a guanine, producing fragments of 100 bp and 193 bp and in the presence of an adenine, the fragment of 293 bp remains intact (Fig. 3).
Fig. 3
Fig. 3

Electrophoretic profile of CXCL12 rs1801157 polymorphism. 10% polyacrylamide gel stained with silver nitrate. Columns 1, 3, 4: GG Genotype presenting two restriction fragments, 100 bp and 193 bp. Column 2: GA Genotype presenting three fragments, 100 bp, 193 pb and 293 bp. Column 5: AA Genotype showing a single fragment of 293 bp

Statistical analysis

Differences in sociodemographic and sexual behavioral data between infected and non-infected women were examined using contingency tables and Pearson’s x2 test. Allele frequency was calculated as [1(h + 2H)]/2 N, where h represents the heterozygous genotype, H is the homozygous genotype, and N is the sample size for each population. Hardy-Weinberg equilibrium in infected and non-infected women was tested using x2 test. Differences in the distribution of genotypes were assessed by x2 test between non-infected and infected women, and among women with or without low- and high-grade squamous intraepithelial lesions. Adjusted Odds Ratio with 95% confidence interval was calculated to estimate the association between HPV presence, sociodemographic, reproductive and sexual behavior features, as well to analyze association of CXCL12 polymorphism with HPV presence and lesions development. Binary logistic regression model adjusted for confounding factors was performed to establish the association between HPV presence and CXCL12 polymorphism. All statistical analysis were performed in SPSS Statistics 22.0 (SPSS Inc., Chicago, Illinois, USA). A p value < 0.05 was considered statistically significant.

Results

In the present study, 364 women were included and categorized as HPV non-infected patients (195/53.6%) and HPV infected patients (169/46.4%) according to the molecular detection of HPV-DNA. Non-infected women mean age was 42 ± 12 years (median = 42), while HPV infected patients mean age was 36 ± 13 years (median = 33).

Sociodemographic characteristics of both groups, HPV infected and HPV non-infected women are presented in Table 1. A higher frequency of HPV was observed in women who had no knowledge about HPV (p = 0.024), were younger than 24 years old (p = 0.001), single (p = 0.002), smokers (p < 0.001) and received less than 1 minimum wage (p = 0.040).
Table 1

Sociodemographic characteristics of HPV positive patients and controls

Variable

HPV non-infected

HPV infected

p value*

OR

CI 95%

p value

n

(%)

n

(%)

Knowledge about HPV

    

0.024

   

 No

36

(19.35)

43

(32.82)

 

1.00

Reference

 

 Have ever heard

106

(57.00)

62

(47.32)

 

0.490

0.258–0.842

0.010

 Yes

44

(23.65)

26

(19.86)

 

0.495

0.257–0.954

0.036

Age (years)

    

0.001

   

 ≤ 24

14

(7.21)

30

(18.63)

 

1.00

Reference

 

 25–34

50

(25.77)

52

(32.29)

 

0.483

0.231–1.021

0.057

 35–44

50

(25.77)

37

(23.00)

 

0.345

0.161–0.741

0.006

 45–54

54

(27.85)

23

(14.28)

 

0.199

0.088–0.443

0.001

 ≥ 55

26

(13.40)

19

(11.80)

 

0.341

0.143–0.812

0.015

Ethnicity

    

0.540

   

 Caucasian

100

(54.06)

58

(44.61)

 

1.00

  

 Brown

61

(33.00)

60

(42.60)

 

1.696

1.048–2.744

0.031

 Black

24

(13.00)

11

(8.50)

 

0.790

0.361–1.730

0.556

 Asian

0

(0.00)

1

(0.80)

 

Monthly incomea

    

0.040

   

 < 1 minimum wage

43

(24.57)

45

(37.81)

 

1.00

Reference

 

 1–3 minimum wages

115

(65.71)

65

(54.62)

 

0.540

0.322–0.906

0.020

 3–5 minimum wages

13

(7.42)

9

(7.57)

 

0.662

0.257–1.706

0.393

 ≥ 5 minimum wages

4

(2.27)

0

(0.00)

 

 

Smoking status

    

0.001

   

 No

163

(84.90)

100

(69.90)

 

1.00

Reference

 

 Yes

29

(15.10)

43

(30.10)

 

2.417

1.419–4.117

0.001

Educational Stageb

    

0.488

   

 Until incomplete fundamental education

58

(31.40)

44

(33.90)

 

1.00

reference

 

 Complete fundamental education

17

(9.20)

18

(13.80)

 

1.396

0.646–3.014

0.396

 Incomplete secondary education

29

(15.70)

16

(12.30)

 

0.727

0.352–1.502

0.390

 Complete secondary education

63

(34.10)

42

(32.30)

 

0.879

0.505–1.528

0.647

 Incomplete higher education

6

(3.20)

6

(4.60)

 

1.318

0.398–4.436

0.651

 Complete higher education

12

(6.40)

4

(3.10)

 

0.439

0.133–1.455

0.178

Marital status

    

0.002

   

 Single

19

(9.80)

39

(24.80)

 

1.00

Reference

 

 Married / Civil partner

143

(73.70)

91

(58.00)

 

0.310

0.169–0.569

0.001

 Divorced

23

(11.90)

19

(12.10)

 

0.402

0.178–0.912

0.029

 Widowed

9

(4.60)

8

(5.10)

 

0.433

0.144–1.300

0.136

aBased on Brazilian minimum wage (approximately U$ 265.00). bBased on Brazilian educational system. *Analysis by two-sided Chi-square (Χ2) test and p < 0.05 set as significance level (SPSS Inc., Chicago, Illinois, USA). Some categories did not complete the total of patients due to lack of data. Significant p values are presented in bold

Sexual and reproductive characteristics data are presented in Table 2. HPV infection was more incident in women who had more than 1 sexual partner during lifetime (p = 0.007), among those who presented lower number of pregnancy (p = 0.017).
Table 2

Sexual behavioral and reproductive characteristics of HPV positive patients and controls

Variable

HPV non-infected

HPV infected

p value*

OR

CI95%

p value

n

(%)

n

(%)

Contraceptive method

    

0.216

   

 No

114

(59.70)

83

(54.20)

 

1.00

Reference

 

 Yes, hormonal

63

(33.00)

52

(34.00)

 

1.134

0.713–1.802

0.569

 Yes, condom

13

(6.80)

13

(8.50)

 

1373

0.605–3.116

0.448

 Yes, both

1

(0.50)

5

(3.30)

 

6.867

0.788–59.882

0.081

Number of pregnancies

    

0.017

   

 0

15

(7.70)

26

(16.30)

 

1.00

Reference

 

 1

33

(17.00)

42

(26.30)

 

0.451

0.243–0.835

0.011

 2

61

(31.50)

35

(21.90)

 

0.540

0.286–1.020

0.058

 3

48

(24.50)

33

(20.60)

 

0.499

0.193–1.043

0.063

 4

21

(10.80)

12

(7.50)

 

0.589

0.245–1.146

0.237

 ≥ 5

16

(8.50)

12

(7.40)

 

1.362

0.623–2.977

0.439

Abortion

    

0.092

   

 No

137

(78.28)

107

(80.45)

 

1.00

Reference

 

 Yes

38

(21.72)

26

(19.55)

 

0.876

0.501–1.533

0.643

Age at first sexual intercourse (years)

    

0.265

   

 ≤17

102

(53.70)

89

(59.70)

 

1.00

Reference

 

 ≥18

88

(46.30)

60

(40.30)

 

0.782

0.506–1.206

0.266

Age at menarche (years)

    

0.379

   

 ≤12

89

(53,65)

82

(54,67)

 

1.00

Reference

 

 ≥13

103

(46,35)

68

(45,33)

 

0.717

0.467–1.101

0.128

Sexual partners during the lifetime

    

0.007

   

 1

76

(40.60)

31

(23.80)

 

1.00

Reference

 

 2–3

53

(28.40)

44

(33.80)

 

2.035

1.142–3.628

0.016

 ≥4

58

(31.00)

55

(42.40)

 

2.325

1.332–4.059

0.003

Sexual partners within the past 6 months

    

0.529

   

 0

26

(13.90)

24

(18.20)

 

1.00

Reference

 

 1

158

(84.50)

103

(78.00)

 

0.706

0.385–1.297

0.262

 ≥2

3

(1.60)

5

(3.80)

 

1.806

0.389–8.382

0.451

*Analysis by two-sided Chi-square (Χ2) test and p < 0.05 as significance level (SPSS Inc., Chicago, Illinois, USA). Some categories did not complete the total of patients due to lack of data. Significant p values are presented in bold

CXCL12 rs1801157 polymorphism genotypes distribution among HPV non-infected and infected patients were in Hardy-Weinberg equilibrium (p ≥ 0.05). A higher frequency of allele A was observed in HPV infected women (p < 0.001) which was confirmed by codominant, dominant and recessive models (Table 3). Considering the allele A variant incidence in both populations, and the number of enrolled women, the power of our analysis was calculated as 99.95%.
Table 3

Association between CXCL12 rs1801157 polymorphism and HPV infection

Model

HPV non-infected N (%)

HPV infected N (%)

OR

CI95%

p value

Codominant model

 GG

147 (75.40)

71 (42.00)

1.00

  

 GA

45 (23.10)

71 (42.00)

3.25

2.044–5.22

< 0.001

 AA

3 (1.50)

27 (16.00)

18.63

5.47–63.49

< 0.001

Dominant model

 GG

147 (75.40)

71 (42.00)

1.00

  

 GA + AA

48 (24.60)

98 (58.00)

4.22

2.70–6.60

< 0.001

Recessive model

 GG + GA

192 (98.50)

142 (84.00)

1.00

  

 AA

3 (1.50)

27 (16.00)

11.80

3.55–39.56

< 0.001

Alleles

 G

339 (86.92)

213 (63.02)

1.00

  

 A

51 (13.08)

125 (36.98)

3.90

2.70–5.63

< 0.001

Analysis by two-sided Chi-square (Χ2) test (p < 0.05 as significance level). OR Odds Ratio; CI Confidence Interval. (SPSS Inc., Chicago, Illinois, USA). Significant p values are presented in bold

In order to confirm whether CXCL12 rs1801157 polymorphism is associated with infection independently of confounding factors, data were adjusted for all confounding factors observed in the previous analysis in a binary logistic regression (Table 4). A significant association between allele A and HPV infection was confirmed in all the seven models proposed, indicating that the polymorphism is independently associated to HPV infection. As observed in model 7, in which data was adjusted for knowledge about HPV, age, monthly income, smoking status, number pregnancies, number of sexual partners, and marital status allele A carriers presented an increased risk for HPV infection [ORADJ = 4.947; CI95% (2.854–8.575), p < 0.001].
Table 4

Association study between CXCL12 rs1801157 and HPV in dominant model infection adjusted for confounder factors

 

Model 1

Model 2

Model 3

Model 4

Model 5

Model 6

Model 7

GG

 OR

1.00

1.00

1.00

1.00

1.00

1.00

1.00

 CI95%

Reference

Reference

Reference

Reference

Reference

Reference

Reference

p value

       

Allele A carrier

 OR

4.004

4.416

4.878

4.836

4.824

4.887

4.947

 CI95%

(2.472–6.483)

(2.677–7.284)

(2.865–8.308)

(2.819–8.296)

(2.811–8.279)

(2.829–8.442)

(2.854–8.575)

p value

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

< 0.001

Logistic regression analysis with HPV as dependent variable (reference group = non-infected women) and CXCL12 rs1801157 polymorphism as explanatory variable, adjusted for several con- founders according to the proposed models (p < 0.05 as significance level). (SPSS Inc., Chicago, Illinois, USA). Significant p values are presented in bold

Model 1: CXCL12 polymorphism adjusted for knowledge about HPV;

Model 2: CXCL12 polymorphism adjusted for knowledge about HPV and age;

Model 3: CXCL12 polymorphism adjusted for knowledge about HPV, age and monthly income;

Model 4: CXCL12 polymorphism adjusted for knowledge about HPV, age, monthly income and smoking status;

Model 5: CXCL12 polymorphism adjusted for knowledge about HPV, age, monthly income, smoking status and number of pregnancies;

Model 6: CXCL12 polymorphism adjusted for knowledge about HPV, age, monthly income, smoking status, number of pregnancies, and number of sexual partners;

Model 7: CXCL12 polymorphism adjusted for knowledge about HPV, age, monthly income, smoking status, number of pregnancies, number of sexual partners and marital status

Considering the polymorphism influence in lesions development, the dominant model was adopted in order to make a better distribution among genotype groups (Table 5). We observed that allele A presence was not associated to LSIL (p = 0.476) compared to women without lesion. However, it was significantly associated to HSIL (p = 0.003) development.
Table 5

Association study between CXCL12 rs1801157 allele A and lesion development

 

n (%)

OR

CI95%

p value

LSIL

 GG

15 (57.70%)

1.000

Reference

 

 GA + AA

11 (42.30%)

1.347

0.594–3.054

 0.476

HSIL

 GG

32 (45.10%)

1.000

Reference

 

 GA + AA

39 (54.90%)

2.239

1.315–3.811

0.003

Data were analyzed compared to patient without lesion. LSIL Low-grade squamous intraepithelial lesion. HSIL High-grade squamous intraepithelial lesion. OR Odds Ratio. CI Confidence Interval. (SPSS Inc., Chicago, Illinois, USA). Significant p values are presented in bold

Discussion

To the best of our knowledge, this is the first study that demonstrated an independent association between CXCL12 rs1801157 polymorphism HPV infection and HSIL.

According to sociodemographic data, HPV was more frequent within patients who had no knowledge about the virus which may indicated lack of information about HPV and also, the ways to avoid virus exposure; among women younger than 24 years old, single and who had more than 1 sexual partner during lifetime.

Young age has been associated in an independent way to HPV infection [2] and it is also in accordance to Sanjosé meta-analysis [17], probably due to the intense sexual activity among younger women, besides that, younger women usually present a larger area of ectopy compared with older adults, what means biological vulnerability to HPV infection because of the easier access to basal epithelial cells [18].

In this study, smoking status was associated to HPV infection (p < 0.001), this could be explained by the fact that tobacco smoking may cause immunosuppression [19, 20]. Smoking may inhibit the immune response to HPV by decreasing Langerhans’ cell in normal epithelium, moreover HPV-infected cells are exposed to tobacco carcinogens that cause DNA damage while HPV oncoprotein E6 block apoptosis [19]. Alam et al. [21] also reported a molecular interaction between benzo[a]pyrene (BaP), a carcinogen found in tobacco smoke, and HPV synthesis, suggesting that BaP might interfere on multiple HPV life cycle functions, such as inducing genome copies, stimulating and/or stabilizing late gene transcripts/capsid proteins and the concomitant virion assembly, potentially enhancing viral persistence, host tissue carcinogenesis, and permissiveness for cancer progression.

Lower pregnancies number (p = 0.017) was also associated to HPV presence. During pregnancy, elevated estrogen and progesterone may lead to the squamous-columnar junction exposure and metaplasia. Parity might increase the risk of cervical cancer because it maintains the cervix transformation zone for many years, facilitating exposure to HPV infection and others cofactors [22]. Another factor that contributes to HPV infection in pregnant women is the immunosuppression due to the steroid hormones increased levels that depress cellular immunity [23] and may also have an effect on HPV replication. Besides, it has been shown that the transcriptional promoter of E6-E7 transforming region of HPV16 contains a steroid hormone receptor-binding element that stimulates HPV E6 and E7 transcription, suggesting a hormonal activation effect on HPV replication [24]. Nonetheless, our data have demonstrated high risk of infection in women with no pregnancies. This might be explained by the fact that the young age of our patients is correlated to lower number of pregnancies (data not shown) as well as higher risk of infection.

Genetic factors have been suggested to play a role in HPV persistence besides environmental and lifestyle factors [25]. Virus persistence and cervical cancer risk may vary among individuals and can be partly explained by individual variations in genes involved in this complex mechanism. A combination of several genetic variants may modulate the risk factors, therefore the identification of susceptibility alleles remains a promising research field [26].

In this context, we analyzed the CXCL12 rs1801157 polymorphism in HPV infection, LSIL and HSIL development. A higher frequency of HPV was observed among allele A carriers, confirmed by binary logistic regression model adjusted for several factors as confounders, demonstrating that CXCL12 rs1801157 is independently associated to HPV infection. Some studies observed that the polymorphism was not a risk factor for cervical cancer development [13, 14, 27] however, none of them have evaluated whether the polymorphism could represent a risk factor for HPV infection as demonstrated in this study.

Precursor lesions can occur as consequence of persistent infection. In the present study, allele A influence in cervical lesion development was also evaluated and a significant association was observed for allele A carriers with HSIL (p = 0.003). Increased gradient of CXCL12 concentration was observed from LSIL to HSIL in women with HR-HPV [28]. Hence, would be expected that allele A carriers were also significantly more frequent in LSIL group, but we did not verify this association. It occurs probably due to the reduced number of our LSIL sampling, which may lead to a lesser analytical power. Further investigation with a larger SIL sampling is currently being performed to confirm this assumption.

CXCL12 has been considered as a standard proinflammatory molecule for a long time, since it attracts leukocytes to inflammatory sites contributing to their activation [9, 29]. Data have suggested that HPV pre-cancerous lesion depend on both the suppression of cellular immunity, driven by the Th1 response and the development of the immunosuppressive Treg profile for neoplastic progression [30]. Significant increased expression of CXCL12, measured by IHC and ELISA, in cervical epithelium, as the neoplastic lesion progressed from preinvasive to invasive cancer, was shown by Jaafar et al. [31]. They also showed that CXCL12 was not expressed in normal cervical squamous or glandular epithelium, which is in accordance with Zanotta et al. [32] who have shown that healthy cervical tissue presented low or no levels of CXCL12. A particular significance correlation was found between CXCL12 and FOXP3 in cervical neoplastic lesion, suggesting that high levels of CXCL12 leads to retention or accumulation of FOXP3+ T cells in progressing cervical cancer [31].

Until present there are no studies about the CXCL12 rs1801157 polymorphism influence in its expression, plasmatic or cervical levels in HPV infection or SIL development, but it has been widely studied in others diseases and tumors, showing conflicting results. De Oliveira et al. [12] demonstrated that allele A carriers breast cancer patients have significant low levels of CXCL12 mRNA in the peripheral blood samples when compared to GG patients. Controversially, Hirata et al. [32] observed in prostate cancer patients that CXCL12 expression was higher in A allele than in allele G carriers.

Immunohistochemistry profile of CXCL12 in colorectal cancer showed weak or negative in normal mucosa and strongly increased in cancer tissues especially in well-differentiated tumors, 73.5% of patients that expressed a strong CXCL12 immunostaining in the membrane and cytomembrane presented AA or GA genotype. By the other hand, 88.6% of those with negative immunoreactivity presented GG genotype [33]. However, in another study with colorectal cancer patients, CXCL12 plasma levels were not related to A allele or GA / AA genotypes [34].

The 3′ untranslated region of genes contains several regulatory motifs that is target of posttranscriptional regulation through interaction with microRNAs, RNA-binding proteins, and long non-coding RNAs, which influence on mRNA turnover, stability and localization. SNPs located in these motifs may prevent miRNA binding and cause mRNA transcript stabilization and increased protein expression [35]. Although the controversial nature of reports about CXCL12 rs1801157 SNP impact on chemokine levels [3639], evidence indicate that miRNAs are involved in protein production and regulation. In silico analysis revealed a seven bases long homologous sequence where rs1801157 is located (i.e., the 4th base is the polymorphic one), which is a putative target of miR941. Thus, the SNP presence may cause loss of miRNA941 binding site. However, interaction analysis between miR941 and the 3’UTR in stem cells from healthy donors was assessed by dual luciferase assays and 3’UTR expression was not affected by co-expression of miR941 [40]. Available knowledge about 3’UTR and miRNAs interaction is poor and deserves better understanding.

Evidence for the involvement of the CXCL12 in the HPV life cycle arose from the abnormal and specific expression of CXCL12 observed in keratinocytes of HPV-productive skin or mucosal lesions [41].

CXCL12 expression levels may increase in keratinocytes as a consequence of HPV genome expression, generating an autocrine signaling loop essential for keratinocyte proliferation and migration [42]. A reasonable explanation for this mechanism is that the CXCL12 proximal promoter in its 5′-flanking and 5′-untranslated region contain six Sp1 binding sites, and Sp1 transcription factor seems to be the major positive regulator of CXCL12 expression [43]. Additionally, after HPV infection of basal epithelial cervical cells, E6 and E7 oncoproteins are expressed, and may bind specifically to protein 1 transcription factor (Sp1). The E6-Sp1 and E7-Sp1 complex can migrate into the nucleus and probably induce the CXCL12 gene expression [44].

Conclusions

More studies are necessary to determine the rs1801157 polymorphism influence in CXCL12 expression and in its cervical levels, in order to establish its influence in HPV infection and in cervical lesion development. However, our work is pioneer in demonstrating the association of CXCL12 rs1801157 polymorphism to HPV infection and HSIL, suggesting it as a promising susceptibility biomarker for HPV infection and the development of cervical lesions.

Abbreviations

3’UTR : 

Untranslated Region

CEP: 

Comitê de Ética em Pesquisa – Universidade Estadual de Londrina

CXCL12: 

Chemokine ligand (family CXC) 12

DNA: 

Desoxyribonucleic acid

dNTP: 

Deoxynucleotide triphosphate

E: 

Early

EDTA: 

Ethylenediaminetetraacetic acid

HPV: 

Human Papillomavirus

HPV-HR: 

HPV High Risk

HR: 

High risk

HSIL: 

High-grade intraepithelial lesion

KCI: 

Potassium chloride

L: 

Late

LCR: 

Long control region

LSIL: 

Low-grade squamous intraepithelial lesion

mRNA: 

Messenger RNA

PCR: 

Polymerase chain reaction

PCR-RFLP: 

Restriction fragment length polymorphism

SDF-1: 

Stromal cell-derived factor 1

SNP: 

Single nucleotide polymorphism

Sp1: 

Specificity protein 1 transcription factor

TE: 

Tris-HCL-EDTA

Declarations

Acknowledgements

All the authors would like to thank the Intermunicipal Consortium of Health of the Middle Paranapanema, Clinic center of the State University of Londrina, Experimental Pathology Postgraduate Program.

Funding

This work was supported by Fundação Araucária - Programa Pesquisa para o SUS (34935.406.36850.19112012).

Availability of data and materials

All data generated or analysed during the current study are included in this published article.

Authors’ contributions

NCMO participated in study design and acquisition of data, experimental procedures, performed statistical analysis and interpretation, and drafted the manuscript. FCS, participated in sample collect and medical records, DNA extraction, statistical analysis. KPT participated in study design, acquisition of data and statistical analysis. ERP, GCMC, MMS, APLP, AMFA, RSF participated in participated in sample collect and DNA extraction. LFLM made possible the sample collect. MAEW have revisited the manuscript for important intellectual content. KBO participated in the design of the study, interpretation of data and given final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by Institutional Ethics Committee Involving Humans at State University of Londrina, Londrina – Paraná (PR), Brazil (CEP/UEL 133/2012; CAAE 05505912.0.0000.5231). Study purpose and procedures were explained to all patients and written informed consent was obtained.

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of molecular genetics and immunology, Department of Pathological Science, Londrina State University, Londrina, PR, Brazil
(2)
Laboratory of study and application of DNA polymorphism, Department of Pathological Science, Londrina State University, Londrina, PR, Brazil

References

  1. Trottier H, Mamud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, et al. Type-scpecific duration of human papillomavirus infections: implications for human papillomavirus screening and vaccination. J Infec. Disease. 2008;197:1436–47.View ArticleGoogle Scholar
  2. Coser J, Boeira TR, Wolf JM, Cerbado K, Simon D, Lunge VR. Cervical human papillomavirus infection and persistence: a clinic-based study in the countryside from South Brazil. Braz J Infect Dis. 2016;20(1):61–8.View ArticleGoogle Scholar
  3. Gravitt PE. The known unknwons of HPV natural history. J Clin Investig. 2011;121(12):4593–9.View ArticleGoogle Scholar
  4. Zur hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384:260–26.View ArticleGoogle Scholar
  5. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11–22.View ArticleGoogle Scholar
  6. Amador-molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013;5(11):2624–42.View ArticleGoogle Scholar
  7. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer chemoter pharmacol. 2010;63:571–82.View ArticleGoogle Scholar
  8. Vandercappellen J, Damme JD, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008;267:226–44.View ArticleGoogle Scholar
  9. Zhou W, Zhang J, Goleniewska K, Dulek DE, Toki S, Newcomb DC, et al. Prostaglandin I2 supresses proinflammatory chemokine expression, CD4 T cell activation, and stat6-independent allergic lung inflammation. J Immunol. 2016;197(15):1577–86.View ArticleGoogle Scholar
  10. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al. Struture and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics. 1995;28:495–500.View ArticleGoogle Scholar
  11. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Alive study, hemophilia growth and development study (hgds), multicenter AIDS cohort study (macs), multicenter hemophilia cohort study (MHCS), san Francisco City cohort (SFCC). Science. 1998;279:389–93.View ArticleGoogle Scholar
  12. De Oliveira KB, Guembarovski RL, Oda JMM, Mantovani MS, Carrera CM, Reiche EMV, et al. CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine. 2011;55(2):260–5.View ArticleGoogle Scholar
  13. Maley SN, Schwatz SM, Johnson LG, Malkki M, Du Q, Daling JR, et al. Genetic variation in CXCL12 and risk of cervical carcinoma: a population-based case-control study. International Journal Immunogenet. 2009;3(6):367–75.View ArticleGoogle Scholar
  14. Roszak A, Misztal M, Sowinska A, Jagodzinski PP. Stromal cell-derived factor-1 G801A polymorphism and the risk factors for cervical cancer. Mol Med Rep. 2015;11:4633–8.View ArticleGoogle Scholar
  15. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. Jama. 1992;265(4):472–7.View ArticleGoogle Scholar
  16. Marangon AV, Guelsin GAS, Visentainer JEL, Borelli SD, Watanabe MAE, et al. The association of the immune response genes to human papillomavirus-related cervical disease in a brazilian population. Biomed Res Int. 2013:1–11.View ArticleGoogle Scholar
  17. Sanjosé S, Castellsagué X, Clifford G, Bruni L, Muñoz N, Boshi FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453–9.View ArticleGoogle Scholar
  18. Hwang lY, Lieberman JA, Ma Y, Farhat S, Moscicki AB. Cervical ectopy and the acquisition of human papillomavirus in adolescents and young women. Obstet Gynecol. 2012;119(6):1164–70.View ArticleGoogle Scholar
  19. Johnson JD, Houchens DP, Kluwe WM, Craign DK, Fisher GL. Effects of mainstream and environmental tobacco smoke on the immune system in animals and humans : a review. Critic rev toxicol. 1990;20(5):369–95.View ArticleGoogle Scholar
  20. Castle PE. How does tobacco smoke contribute to cervical carcinogenesis? J Virol. 2008;82(12):6084–6.View ArticleGoogle Scholar
  21. Alam S, Conway MJ, Chen HS. Meyers c. cigarette smoke carcinogen benzo[a]pyrene enhances human papillomavirus synthesis. J Virol. 2007;82(2):1053–8.View ArticleGoogle Scholar
  22. Munoz N, Franceschini S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and human papillomavirus in cervical cancer: the iarc multicentric case-control study. Lancet. 2002;359(9312):1093–101.View ArticleGoogle Scholar
  23. Banura C, Franceschini S, va Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F, et al. Prevalence, incidence and clearence of human papillomavirus infection among young primiparous pregnant women in Kampala, Uganda. Int J Cancer. 2008;123:2180–7.View ArticleGoogle Scholar
  24. Gloss B, Bernard HU, Seedorf K. Klock G. the upstream regulatory region of the human papillomavirus 16 contains an E2 protein-independent enhancer which is specifc for cervical carcinoma cells and regulated by glucocorticoid hormone. EMBO J. 1987;6(12):3735–43.View ArticleGoogle Scholar
  25. Tan SC, Ankathil R. Genetic susceptibility to cervical cancer: role of common polymorphisms in apoptosis-related genes. Tumor Biol. 2015;36(9):6633–44.View ArticleGoogle Scholar
  26. Bodily J, Laimins LA. Persistence of human papillomavirus infection : keys to malignant progression. Trends Microbiol. 2011;19(1):33–9.View ArticleGoogle Scholar
  27. Tee YT, Yang SF, Wang PH, Tsai HT, Lin LY, Liao CL, et al. G801a polymorphism of human stromal cell-derived factor 1 gene raises no susceptibility to neoplastic lesions of uterine cervix. Int J Gynecol Cancer. 2012;22(8):1297–302.View ArticleGoogle Scholar
  28. Zanotta N, Tornesello ML, Annunziata C, Stellato G, Buonaguro FM, Comar M. Candidate soluble immune mediators in young women with high-risk human papillomavirus infection: high expression of chemokines promoting angiogenesis and cell proliferation. PLoS One. 2016;11(3):1–14.View ArticleGoogle Scholar
  29. Timotijević G, Mostarica MS, Miljković D. CXCL12: role in neuroinflammation. Int J Biochem Cell Biol. 2012;44(6):838–41.View ArticleGoogle Scholar
  30. Strickler HD, Martinson J, Desai S, Xie X, Burk RD, Anastos K, et al. The relation of plasmacytoid dendritic cells (PDCS) and regulatory T-cells (Tregs) with HPV persistence in HIV-infected and HIV- uninfected women. Viral Immunol. 2014;27:20–5.View ArticleGoogle Scholar
  31. Jaafar F, Righi E, Lindstorm V, Linton C, Nohadani M, Noorden SV, et al. Correlation of CXCL12 expression and FOXP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am J Pathol. 2009;175:1525–35.View ArticleGoogle Scholar
  32. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, et al. CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res. 2007;13(17):5056–62.View ArticleGoogle Scholar
  33. Amara S, Chaar I, Khiari M, Ouinissi D, Hmida AB, Mzabi SR, et al. Relationship between SDF-1G801A polymorphism and its expression in Tunisian patients with colorectal cancer. J Immunoass Immunochem. 2015;36:182–94.View ArticleGoogle Scholar
  34. Dimberg J, Hugander A, Löfgren S, Wagsäter D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int J Mol Med. 2007;19(1):11–5.PubMedGoogle Scholar
  35. Schwerk J, Savan R. Translating the untranslated region. J Immunol. 2015;195:2963–71.View ArticleGoogle Scholar
  36. Xiao Q, Ye S, Oberhollenzer F, Mayr A, Jahangiri M, Willeit J, et al. SDF1 gene variation is associated with circulating SDF1α level and endothelial progenitor cell number – the Burneck study. PLoS One. 2008;3(12):e6041.View ArticleGoogle Scholar
  37. Arya SK, Ginsberg CC, Davis-Warren A, D’Costa J. In vitro genotype of SDF1 gene mutant that delays the onset of human immunodeficiency virus disease in vivo. J hum virol. 1999;2(3):133–8.PubMedGoogle Scholar
  38. Soriano A, Martínez C, García F, Plana M, Palou E, Lejeune M, et al. Plasma stromal cell – derived factor (SDF) – 1 levels, SDF1 – 3’A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistence to humam immunodeficiency virus tyoe 1 infection and its progression. J Infect Dis. 2002;186(7):922–31.View ArticleGoogle Scholar
  39. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, et al. miR-126 and miR126* repress recruitmentof mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15(3):284–94.View ArticleGoogle Scholar
  40. Schulz M, Karpova D, Spohn G, Damert A, Seifried E, Binder V, et al. Variant rs1801157 in the 3’UTR of SDF-1β does not explain variability of healthy-donor G-CSF responsiveness. PLoS One. 2015;10(3):e0121859.View ArticleGoogle Scholar
  41. Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood. 2005;105(6):2449–58.View ArticleGoogle Scholar
  42. Meuris F, Carthagena L, Jaracz-Ros A, Gaudin F, Cutolo P, Deback C, et al. The CXCL12/CXCR4 signaling pathway: a new susceptibility factor in human papillomavirus pathogenesis. PLoS Pathog. 2016;12(12):1–25.View ArticleGoogle Scholar
  43. García-Moruja C, Alonso-Lobo JM, Rueda P, Torres C, González N, Bermejo M, et al. Functional characterization of SDF-1 proximal promoter. J Mol Biol. 2005;348(1):43–62.View ArticleGoogle Scholar
  44. Peralta-Zaragoza O, Bermúdez-Morales V, Gutiérrez-Xicotencatl L, Alcocer-González J, Recillas-Targa F, Madrid-Marina V. E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor 1 promoter throughout SP1 recognition sequence. Viral Immunol. 2006;19(3):468–48.View ArticleGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement